CA-CYARA
14.9.2022 17:01:37 CEST | Business Wire | Press release
Cyara, provider of the award-winning Automated Customer Experience (CX) Assurance Platform, today announced it closed FY22 with more than 30% growth in revenue, a 95% customer retention rate, a Customer Net Promoter Score (NPS) of 70 and 10 billion seconds of synthetic CX testing traffic annually.
In January, Cyara received over $350 million in funding from leading investment firm K1 Investment Management (K1) to support accelerated growth, driving further expansion of the contact testing market. Following the funding, Cyara acquired industry-leading automated chatbot testing company Botium. The strategic acquisition added chatbot and conversational artificial intelligence (AI) testing and optimization capabilities to Cyara's product portfolio, solidifying the company’s position as the global leader in the CX testing and assurance market.
New Features & Services
Recently, Cyara added Cyara Botium to its solution portfolio. Botium tests and monitors the performance of chatbots and conversational AI. It is the only solution on the market offering seamless and comprehensive CX journey assurance from digital to voice agents. Botium enables brands to improve and continuously test the customer chatbot experience across all channels and platforms in all phases of the chatbot development lifecycle.
“In today’s digital economy, testing digital CX is a critical function for companies in every industry, so the release of Cyara Botium was a natural addition to our product arsenal. It has already made a positive impact for many of our customers,” said Alok Kulkarni, CEO and Co-founder of Cyara. “Our goal is to ensure that self-service CX solutions such as chatbots and interactive voice response (IVR) systems are improving customer journeys -- not causing customers additional frustration -- all while increasing productivity and minimizing costs.”
Additional products and offerings that Cyara unveiled in FY22 include:
- LiveVQ: A solution that delivers last mile assurance for the hybrid workforce by monitoring cloud connectivity, agent applications and technology infrastructure in real time to ensure voice quality for at-home and remote agents.
- Toll-Free Fast Check: A concierge-style, white-glove service that reduces the manual, labor-intensive task of managing and testing toll-free numbers -- just in time for health insurance Open Enrollment and retail holiday season readiness.
- CX Test Automation Maturity Model: An innovative, easy-to-navigate self-assessment that enables organizations to determine how advanced their approach to automated CX testing is and see how their current level of test automation measures up to industry best practices.
- GDPR Compliance Testing: A free service for organizations' chatbots in both English and German that reduces the risk of fines associated with non-compliance, allowing bots to quickly and accurately assist organizations' customers who want to know how their data is being stored.
- Support for NICE InContact: Cyara released virtual agents for NICE InContact, enabling customers on that platform to test call routing and data passing functionality
- Greater Flexibility Scheduling Load Tests: Cyara delivered several features over the course of the year making it easier for its customers to schedule and run load tests, including a self-service booking calendar, as well as the ability to run small load tests without a booking at all. This helps customers reduce friction and increase the frequency of load testing to enable continuous testing.
Company Growth & Expansion of Executive Team
Cyara continues to grow its employee ranks with headcount growing over 70%. The company strengthened its executive bench with several new hires in FY22, including Jeremy Braidish, Chief People Officer (CPO). Jeremy brings 20+ years of human resources (HR) experience to drive Cyara’s global HR functions and strategy, in addition to talent acquisition and development.
Key Partnerships
Today, more than 250 high-profile global brands trust Cyara’s SaaS solution to test, monitor and manage CX technology, which enables them to deliver stellar experiences for customers.
FY22 saw Cyara establish new alliances with Carahsoft, ConvergeOne, Waterfield and VIS Global as well as expanding relationships with partners like Genesys, AWS and Verizon to grow new channel ACV bookings by 30% year on year.
Cyara’s successful and unique approach to CX optimization has resulted in the Cyara Accelerator being made available on Genesys AppFoundry.
Industry Recognition & Accolades
The growing adoption and continued success of Cyara’s platform has been recognized in 12 industry awards, including:
- Silver Stevie® Award for “Sales or Customer Service Solutions Technology Partner of the Year” and “Best Contact Center Solution”
- Product of the Year Award from CUSTOMER Magazine
- Remote Work Pioneer Award and Communications Solutions Products of the Year Award from TMC
- Gold Globee winner in the “Test, Measurement and Monitoring Innovation” category from Golden Bridge Business and Innovation Awards
About Cyara’s Automated CX Assurance Platform
The award-winning Cyara Automated CX Assurance Platform enables companies to deliver better CX with less effort, cost, and risk. Cyara supports the entire CX software development lifecycle, from design to functional and regression testing, load testing, chatbot testing and production monitoring, ensuring enterprises can build flawless customer journeys across voice and digital channels.
About Cyara
Cyara is the world’s leading Automated Customer Experience (CX) Assurance platform, headquartered in Silicon Valley. Cyara’s cloud-based omnichannel assurance solutions for voice quality and chatbot testing accelerate the delivery of flawless customer journeys for enterprises while reducing the risk of customer-facing defects. Every day, major global brands trust the Cyara Platform to deliver customer smiles at scale. For more information, please visit cyara.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005308/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom